Abstract
Identification and documentation of adverse drug events (ADEs) is an essential prerequisite for the evaluation of the therapeutic value of drug treatment. The present article focuses on the methods used to elicit ADEs during the early drug development phase. These methods vary in the sources of information (patient or physician) used to identify and document ADEs and in the areas (e.g., general scales or special motor performance scales) studied for ADEs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
